Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc. Warrants
- Market cap
- $201.82K
Your view on ERNAW
Overview
What the company does, where it operates, and who runs it.
About Ernexa Therapeutics Inc. Warrants
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sanjeev Luther
- Headquarters
- 1035 Cambridge Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sanjeev Luther
- Headquarters
- 1035 Cambridge Street, Cambridge, MA, US
Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions.
Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis.
Ernexa Therapeutics has secured a licensing agreement with Factor Bioscience Limited. The company, founded in 2018 and headquartered in Cambridge, Massachusetts, was formerly named Eterna Therapeutics Inc., before officially changing to Ernexa Therapeutics in March 2025.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Ernexa Therapeutics Inc. Warrants. Starting points for Ernexa Therapeutics Inc. Warrants: EPS -$8.95, beta 2.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Ernexa Therapeutics Inc. Warrants. Trailing twelve-month EPS for Ernexa Therapeutics Inc. Warrants stands at -$8.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Dec 2025 | Next yearYear to Dec 2026 |
|---|---|---|
| Average estimate | −$4,050.00 | −$18.02 |
| Lowest estimate | −$4,050.00 | −$18.02 |
| Highest estimate | −$4,050.00 | −$18.02 |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Revenue estimates
| Total | This yearYear to Dec 2025 | Next yearYear to Dec 2026 |
|---|---|---|
| Average estimate | $32.81M | $75.35M |
| Lowest estimate | $32.81M | $75.35M |
| Highest estimate | $32.81M | $75.35M |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Ernexa Therapeutics Inc. Warrants. Ernexa Therapeutics Inc. Warrants has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BNTXBioNTech SE | Healthcare | NASDAQ | $20.1B | ||
| BOLDBoundless Bio, Inc. | Healthcare | NASDAQ | $54.8M | ||
| BOLTBolt Biotherapeutics, Inc. | Healthcare | NASDAQ | $12.8M | ||
| BOT.AXBotanix Pharmaceuticals Limited | Healthcare | ASX | — | ||
| BOVNFBioInvent International AB (publ) | Healthcare | OTC | $216.4M | ||
| BPMUFBasilea Pharmaceutica AG | Healthcare | OTC | $871.3M | ||
| BPTHBio-Path Holdings, Inc. | Healthcare | OTC | $554,529 | ||
| BPTSYBiophytis S.A. | Healthcare | OTC | $189,402 | ||
| BRAXFBraxia Scientific Corp. | Healthcare | OTC | $30,017 | ||
| BRCTFBioArctic AB (publ) | Healthcare | OTC | $3.4B | ||
| BRIBFBrii Biosciences Limited | Healthcare | OTC | $135.7M | ||
| BRNSBarinthus Biotherapeutics plc | Healthcare | NASDAQ | $30.2M | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Ernexa Therapeutics Inc. Warrants executives and directors. Shares of Ernexa Therapeutics Inc. Warrants have traded between $0.04 and $0.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Ernexa Therapeutics Inc. Warrants.